Alladapt Announces Initiation of Encore Open-Label Extension Study for its Harmony Phase 1/2 Study of ADP101 for Treatment of Food Allergy
March 17, 2022 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
Alladapt Announces Completion of Patient Enrollment in its Phase 1/2 Harmony Study of ADP101 for Treatment of Food Allergy
January 04, 2022 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to...
Alladapt Initiates Buildout of New Manufacturing Facility for Production of Novel, Investigational Oral Immunotherapeutic Designed to Address a Broad Range of Food Allergies
August 19, 2021 07:00 ET
|
Alladapt Immunotherapeutics Inc.
ADP101 is a singular optimized, pharmaceutical-grade oral immunotherapy candidate currently in a Phase 1/2 clinical trial for patients with mono- and multi-food allergies Facility intended to support...
Alladapt Appoints Glenn Reicin as Chief Financial Officer
June 22, 2021 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to...